Skip to main content
. 2020 Apr 21;127:104380. doi: 10.1016/j.jcv.2020.104380

Table 3.

Ongoing phase III trials assessing tocilizumab monotherapy in patients with COVID-19.

Trial (NCT identifier) Population (estimated enrollment) Intervention Comparator Primary outcome Estimated completion
COVACTA (NCT04320615) Hospitalized adults with COVID-19 with SPO2 ≤ 93% or PaO2/FiO2 < 300 mg (n = 330) TCZ 8 mg/kg IV up to 800 mg x 1 dose (additional dose may be given if symptoms worsen/no improvement shown) Placebo Clinical status assessed using a 7-category ordinal scale at day 28 September 30, 2021

Abbreviations: IV: intravenous; PaO2/FiO2: ratio of arterial oxygen pressure to fractional inspired oxygen; SPO2: oxygen saturation; TCZ: tocilizumab.